Trade Pluri Inc. - PLUR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.4660 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.487 |
| Open | 4.387 |
| 1-Year Change | 451.82% |
| Day's Range | 4.157 - 4.387 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 4.1570 | -0.2300 | -5.24% | 4.3870 | 4.3870 | 4.1570 |
| Feb 20, 2025 | 4.4870 | -0.0300 | -0.66% | 4.5170 | 4.5170 | 4.4370 |
| Feb 19, 2025 | 4.4570 | -0.0700 | -1.55% | 4.5270 | 4.5470 | 4.4370 |
| Feb 18, 2025 | 4.4270 | 0.0200 | 0.45% | 4.4070 | 4.4670 | 4.3870 |
| Feb 14, 2025 | 4.4470 | 0.0500 | 1.14% | 4.3970 | 4.4670 | 4.3970 |
| Feb 13, 2025 | 4.4170 | -0.0300 | -0.67% | 4.4470 | 4.4770 | 4.4070 |
| Feb 12, 2025 | 4.3070 | 0.1000 | 2.38% | 4.2070 | 4.3470 | 4.2070 |
| Feb 11, 2025 | 4.2770 | -0.0200 | -0.47% | 4.2970 | 4.2970 | 4.2770 |
| Feb 10, 2025 | 4.2470 | -0.1900 | -4.28% | 4.4370 | 4.4370 | 4.1370 |
| Feb 7, 2025 | 4.4070 | 0.2100 | 5.00% | 4.1970 | 4.4070 | 4.1870 |
| Feb 6, 2025 | 4.2170 | 0.0400 | 0.96% | 4.1770 | 4.5070 | 4.0070 |
| Feb 5, 2025 | 4.3270 | -0.0900 | -2.04% | 4.4170 | 4.4270 | 4.0270 |
| Feb 4, 2025 | 4.2270 | -0.2400 | -5.37% | 4.4670 | 4.6570 | 4.0370 |
| Feb 3, 2025 | 4.1070 | -0.0800 | -1.91% | 4.1870 | 4.3470 | 3.9970 |
| Jan 31, 2025 | 4.2870 | 0.1900 | 4.64% | 4.0970 | 4.3170 | 3.9870 |
| Jan 30, 2025 | 4.1570 | 0.0300 | 0.73% | 4.1270 | 4.3470 | 3.9970 |
| Jan 29, 2025 | 4.3270 | 0.2800 | 6.92% | 4.0470 | 4.3270 | 4.0470 |
| Jan 28, 2025 | 4.3170 | -0.0200 | -0.46% | 4.3370 | 4.3370 | 4.3170 |
| Jan 27, 2025 | 4.1270 | -0.0800 | -1.90% | 4.2070 | 4.6170 | 4.0370 |
| Jan 24, 2025 | 4.1770 | -0.1700 | -3.91% | 4.3470 | 4.3970 | 4.1770 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Pluri Inc. Company profile
About Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
Financial summary
BRIEF: For the six months ended 31 December 2021, Pluristem Therapeutics Inc. revenues was not reported. Net loss increased 6% to $22.4M. Higher net loss reflects General and administrative expenses increase of 30% to $4.8M (expense), Stock-based Compensation in SGA increase of 9% to $4.6M (expense), Research & Development Expense decrease of 75% to $72K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to -$0.70.
Equity composition
Common Stock $0.00001 Par, 01/13, 100M auth., 58,333,206 issd. Insiders control 11.74%. IPO: NA. 11/07,1-for-200 reverse stock split. 11/07, Name changed from Pluristem Life Systems, Inc. 12/07, Exchanged changed from OTC Bulletin Board to NASDAQ.
| Industry: | Biotechnology & Medical Research (NEC) |
Matam Park Building 5
HAIFA
3508409
IL
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com